Barclays downgrades Stryker outlook to "underweight" — 5 key notes

Spinal Tech

Barclays downgraded Stryker shares, according to a Woodbridge Daily report.

Here are five things to know about the downgrade:

 

1. Stryker's shares currently have an "underweight" rating, down from "equal weight."

 

2. Price target for the shares went from $88 to $92 per share.

 

3. Stryker stock price is expected to reach $99.79 in the short term.

 

4. There are 14 analysts agreeing with the consensus, with a higher short term estimate at $105 and lower at $88.

 

5. The market cap is $34.7 billion with 378.9 million shares outstanding.

 

Stryker shares did drop 1.56 percent over the past week but the big picture remains bullish, according to the report, and shares posted positive gains of 1.17 percent over the last four weeks.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like

 

Featured Webinars

Featured Whitepapers